Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CGT Catapult

- PMLiVE

CGT Catapult establishes industry safety consortium for cell therapies

A universal safety test for CGTs could reduce both costs and wait times for treatment

- PMLiVE

Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

- PMLiVE

A first for Bluebird and Europe as gene therapy Zynteglo approved

Will product be priced over $1m?

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

Catalent preps for complex therapy boom with $1.2bn Paragon buy

Reflects growing investment in cell and gene therapies

- PMLiVE

Weekly industry appointments

GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board

Cell and gene therapies: on course for commercial success?

Funding and reimbursement of cell and gene therapies pose a major challenge as payers consider how to evaluate a commercial proposition that is completely divergent from the traditional pharmaceutical model....

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links